These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 30599853)

  • 1. Genomics of non-small cell lung cancer (NSCLC): Association between CT-based imaging features and EGFR and K-RAS mutations in 122 patients-An external validation.
    Rizzo S; Raimondi S; de Jong EEC; van Elmpt W; De Piano F; Petrella F; Bagnardi V; Jochems A; Bellomi M; Dingemans AM; Lambin P
    Eur J Radiol; 2019 Jan; 110():148-155. PubMed ID: 30599853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.
    Rizzo S; Petrella F; Buscarino V; De Maria F; Raimondi S; Barberis M; Fumagalli C; Spitaleri G; Rampinelli C; De Marinis F; Spaggiari L; Bellomi M
    Eur Radiol; 2016 Jan; 26(1):32-42. PubMed ID: 25956936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.
    Shiri I; Maleki H; Hajianfar G; Abdollahi H; Ashrafinia S; Hatt M; Zaidi H; Oveisi M; Rahmim A
    Mol Imaging Biol; 2020 Aug; 22(4):1132-1148. PubMed ID: 32185618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CT and clinical characteristics that predict risk of EGFR mutation in non-small cell lung cancer: a systematic review and meta-analysis.
    Zhang H; Cai W; Wang Y; Liao M; Tian S
    Int J Clin Oncol; 2019 Jun; 24(6):649-659. PubMed ID: 30835006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of feature harmonization on radiogenomics analysis: Prediction of EGFR and KRAS mutations from non-small cell lung cancer PET/CT images.
    Shiri I; Amini M; Nazari M; Hajianfar G; Haddadi Avval A; Abdollahi H; Oveisi M; Arabi H; Rahmim A; Zaidi H
    Comput Biol Med; 2022 Mar; 142():105230. PubMed ID: 35051856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CT-based non-invasive identification of the most common gene mutation status in patients with non-small cell lung cancer.
    Chen Z; Gao S; Ding C; Luo T; Xu J; Xu S; Li S
    Med Phys; 2024 Mar; 51(3):1872-1882. PubMed ID: 37706584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Machine Learning-Based Radiomics Signatures for EGFR and KRAS Mutations Prediction in Non-Small-Cell Lung Cancer.
    Le NQK; Kha QH; Nguyen VH; Chen YC; Cheng SJ; Chen CY
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
    Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma.
    Liu Y; Kim J; Qu F; Liu S; Wang H; Balagurunathan Y; Ye Z; Gillies RJ
    Radiology; 2016 Jul; 280(1):271-80. PubMed ID: 26937803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.
    Guan J; Xiao NJ; Chen M; Zhou WL; Zhang YW; Wang S; Dai YM; Li L; Zhang Y; Li QY; Li XZ; Yang M; Wu HB; Chen LH; Liu LY
    Medicine (Baltimore); 2016 Jul; 95(30):e4421. PubMed ID: 27472739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.
    Yip SS; Kim J; Coroller TP; Parmar C; Velazquez ER; Huynh E; Mak RH; Aerts HJ
    J Nucl Med; 2017 Apr; 58(4):569-576. PubMed ID: 27688480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and radiological predictors of epidermal growth factor receptor mutation in nonsmall cell lung cancer.
    Dang Y; Wang R; Qian K; Lu J; Zhang H; Zhang Y
    J Appl Clin Med Phys; 2021 Jan; 22(1):271-280. PubMed ID: 33314737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiomics for the prediction of EGFR mutation subtypes in non-small cell lung cancer.
    Li S; Ding C; Zhang H; Song J; Wu L
    Med Phys; 2019 Oct; 46(10):4545-4552. PubMed ID: 31376283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and computed tomography characteristics of non-small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR-negative lung cancer.
    Mori M; Hayashi H; Fukuda M; Honda S; Kitazaki T; Shigematsu K; Matsuyama N; Otsubo M; Nagayasu T; Hashisako M; Tabata K; Uetani M; Ashizawa K
    Thorac Cancer; 2019 Apr; 10(4):872-879. PubMed ID: 30811109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using contrast-enhanced CT and non-contrast-enhanced CT to predict EGFR mutation status in NSCLC patients-a radiomics nomogram analysis.
    Yang X; Liu M; Ren Y; Chen H; Yu P; Wang S; Zhang R; Dai H; Wang C
    Eur Radiol; 2022 Apr; 32(4):2693-2703. PubMed ID: 34807270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrast Enhanced CT Radiogenomics in a Retrospective NSCLC Cohort: Models, Attempted Validation of a Published Model and the Relevance of the Clinical Context.
    Kohan A; Hinzpeter R; Kulanthaivelu R; Mirshahvalad SA; Avery L; Tsao M; Li Q; Ortega C; Metser U; Hope A; Veit-Haibach P
    Acad Radiol; 2024 Jul; 31(7):2953-2961. PubMed ID: 38383258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
    Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis.
    Chen L; Zhou Y; Tang X; Yang C; Tian Y; Xie R; Chen T; Yang J; Jing M; Chen F; Wang C; Sun H; Huang Y
    Int J Oncol; 2019 Jan; 54(1):370-380. PubMed ID: 30431083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients.
    Lee SM; Bae SK; Jung SJ; Kim CK
    Clin Nucl Med; 2015 Dec; 40(12):950-8. PubMed ID: 26359571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of CT radiogenomic and clinical characteristics between EGFR and KRAS mutations in lung adenocarcinomas.
    Lv J; Zhang H; Ma J; Ma Y; Gao G; Song Z; Yang Y
    Clin Radiol; 2018 Jun; 73(6):590.e1-590.e8. PubMed ID: 29454587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.